{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:20:22Z","timestamp":1790061622528,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:31:52Z","timestamp":1676665912000},"page":"83-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-1695","authenticated-orcid":false,"given":"Julia","family":"Lai-Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-6640","authenticated-orcid":false,"given":"Andrisha-Jade","family":"Inderjeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Lisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-4572","authenticated-orcid":false,"given":"Claudia","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-7807","authenticated-orcid":false,"given":"Michael","family":"Jefford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2023.02.005_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2023.02.005_bib2","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.005_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing metastatic melanoma in 2022: a clinical review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.005_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2023.02.005_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.02.005_bib8","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2021.39.15_suppl.9507","article-title":"Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma","volume":"39","author":"Dummer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.02.005_bib9","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1200\/JCO.2022.40.16_suppl.9522","article-title":"Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067","volume":"40","author":"Hodi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.005_bib10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.005_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.005_bib12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.005_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.005_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.005_bib17","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.02.005_bib21","series-title":"Quality of life: the assessment, analysis and reporting of patient-reported outcomes","author":"Fayers","year":"2016"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.005_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.1994.12.3.608","article-title":"Lessons learned from measuring health-related quality of life in oncology","volume":"12","author":"Osoba","year":"1994","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.005_bib23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/pon.4290","article-title":"Systematic review of psychosocial outcomes for patients with advanced melanoma","volume":"26","author":"Dunn","year":"2017","journal-title":"Psycho Oncol"},{"issue":"10336","key":"10.1016\/j.ejca.2023.02.005_bib24","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.ejca.2023.02.005_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9500","article-title":"Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2023.02.005_bib26","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/annonc\/mdp255","article-title":"A systematic review of health-related quality of life in cutaneous melanoma","volume":"20","author":"Cornish","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejca.2016.10.008","article-title":"A systematic review examining factors influencing health related quality of life among melanoma cancer survivors","volume":"69","author":"Hamel","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.005_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/pcmr.12647","article-title":"Quality-of-life outcomes in patients with advanced melanoma: a review of the literature","volume":"30","author":"Malkhasyan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2023.02.005_bib29","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2023.02.005_bib30","series-title":"JBI Manual for evidence synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.ejca.2023.02.005_bib31","series-title":"JBI manual for evidence synthesis","article-title":"Chapter 3: systematic reviews of effectiveness","author":"Tufanaru","year":"2020"},{"key":"10.1016\/j.ejca.2023.02.005_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","article-title":"Health-related quality of life results from the phase III CheckMate 067 study","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.005_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.005_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2019.09.019","article-title":"Health-related quality of life in patients with fully resected BRAF(V600) mutation-positive melanoma receiving adjuvant vemurafenib","volume":"123","author":"Schadendorf","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.005_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","article-title":"Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Schadendorf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.005_bib37","doi-asserted-by":"crossref","first-page":"e000260","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.02.005_bib38","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","article-title":"Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study","volume":"27","author":"Long","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.005_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","article-title":"Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma","volume":"67","author":"Schadendorf","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.02.005_bib41","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s11136-020-02520-7","article-title":"Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings","volume":"29","author":"Joseph","year":"2020","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.005_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11764-019-00770-0","article-title":"The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors","volume":"13","author":"Lai-Kwon","year":"2019","journal-title":"J Cancer Survivorship"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00520-019-04818-w","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O'Reilly","year":"2020","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib44","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00520-019-05168-3","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2023.02.005_bib45","article-title":"Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy","author":"Levy","year":"2018","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/NCC.0000000000000683","article-title":"Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \"Real-World\" data","volume":"43","author":"Milne","year":"2020","journal-title":"Cancer Nurs"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.005_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12885-021-08032-y","article-title":"Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study","volume":"21","author":"Dalle","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.02.005_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health Qual Life Outcome"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib49","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00520-017-3621-z","article-title":"Patient perspectives on ipilimumab across the melanoma treatment trajectory","volume":"25","author":"Shuk","year":"2017","journal-title":"Support Care Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.02.005_bib50","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1200\/JCO.2019.37.15_suppl.9588","article-title":"Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III macroscopic melanoma: a matched cohort study","volume":"37","author":"Boekhout","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2192480","article-title":"Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab","volume":"2020","author":"Rogiers","year":"2020","journal-title":"J Immunol Res"},{"issue":"13","key":"10.1016\/j.ejca.2023.02.005_bib52","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.005_bib53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/bjc.2017.488","article-title":"Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma","volume":"118","author":"Dr\u00e9no","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.02.005_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2021.04.028","article-title":"Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS)","volume":"152","author":"Gogas","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.005_bib56","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","article-title":"Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine","volume":"25","author":"Grob","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.005_bib57","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/annonc\/mdt580","article-title":"Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study","volume":"25","author":"Schadendorf","year":"2014","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2023.02.005_bib58","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.005_bib59","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.02.005_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.005_bib61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients' health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2023.02.005_bib62","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2217\/fon-2018-0772","article-title":"Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy","volume":"15","author":"Bossi","year":"2019","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib63","doi-asserted-by":"crossref","first-page":"e036059","DOI":"10.1136\/bmjopen-2019-036059","article-title":"i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol","volume":"10","author":"Hyatt","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.005_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092969","article-title":"Feasibility and acceptability of fear-less: a stepped-care program to manage fear of cancer recurrence in people with metastatic melanoma","volume":"9","author":"Lynch","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2023.02.005_bib65","series-title":"International society of quality of life research 29th annual conference","article-title":"Phase I of the development of an EORTC QOL module for patients with metastatic melanoma","author":"Egeler","year":"2022"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.005_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.soc.2010.09.002","article-title":"Assessment of patient-reported outcomes in patients with melanoma","volume":"20","author":"Cormier","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.005_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","article-title":"The experience of financial toxicity among advanced melanoma patients treated with immunotherapy","volume":"39","author":"Thom","year":"2021","journal-title":"J Psychosoc Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2023.112937","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:52:40Z","timestamp":1686883960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":67,"alternative-id":["S0959804923000825"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}